You just read:

Daiichi Sankyo's Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosynovial Giant Cell Tumor Patients in New Long-Term Analysis Presented at 2019 ASCO Annual Meeting

News provided by

Daiichi Sankyo Company, Limited

01 Jun, 2019, 13:00 BST